A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients with Refractory Hyperlipidemia

A single dose of the experimental medicine VERVE-201 will be tested in people for the first time, to see if it can safely lower cholesterol in patients whose standard treatments have failed. These patients have refractory hyperlipidemia—dangerously high levels of LDL cholesterol that persist despite maximum doses of statins and other drugs. LDL cholesterol builds up in artery walls, narrowing them and raising the risk of heart attacks and strokes. Current treatments often cannot bring these patients to their recommended cholesterol targets, leaving them vulnerable to cardiovascular events. VERVE-201 works by editing a single gene called ANGPTL3, permanently turning it off. This gene normally produces a protein that raises LDL levels; disabling it is known to lower cholesterol. The study’s primary goal is safety, not efficacy. Participants will be monitored for one year, with a long-term follow-up extending to 15 years. If VERVE-201 proves safe and effective, it could offer a one-time treatment for patients who currently face a lifetime of inadequate cholesterol control. This would directly reduce their risk of heart attack and stroke—the leading causes of death worldwide. The research is an early-stage, first-in-human trial, so practical use remains years away, but it represents a fundamental shift from daily pills to permanent genetic intervention.